Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 14 May 2024

Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis

in Cancer Molecular Targets and Therapeutics

Mengzhang Xie
Qi Huang
Taojun Gong
Yitian Wang
Zhuangzhuang Li
Minxun Lu
Yi Luo
Li Min
Yong Zhou
Chongqi Tu

Frontiers in Oncology

doi 10.3389/fonc.2024.1399574

1,267 views
1 citation

Original Research

Published on 13 May 2024

Chloroquine-induced DNA damage synergizes with DNA repair inhibitors causing cancer cell death

in Cancer Molecular Targets and Therapeutics

Diego Iglesias-Corral
Paula García-Valles
Nuria Arroyo-Garrapucho
Elena Bueno-Martínez
Juan Manuel Ruiz-Robles
María Ovejero-Sánchez
Rogelio González-Sarmiento
Ana Belén Herrero

Frontiers in Oncology

doi 10.3389/fonc.2024.1390518

2,133 views
1 citation

Review

Published on 10 May 2024

Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment

in Cancer Molecular Targets and Therapeutics

Szu-Aun Long
Amber M. Amparo
Grace Goodhart
Syed A. Ahmad
Andrew M. Waters

Frontiers in Oncology

doi 10.3389/fonc.2024.1402128

5,976 views
2 citations

Review

Published on 10 May 2024

The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies

in Cancer Molecular Targets and Therapeutics

Oluwaseun Adebayo Bamodu
Chen-Chih Chung
Thomas R. Pisanic
Alexander T. H. Wu

Frontiers in Oncology

doi 10.3389/fonc.2024.1404628

1,525 views

Review

Published on 08 May 2024

The use of photodynamic therapy in medical practice

in Cancer Molecular Targets and Therapeutics

David Aebisher
Kacper Rogóż
Angelika Myśliwiec
Klaudia Dynarowicz
Rafał Wiench
Grzegorz Cieślar
Aleksandra Kawczyk-Krupka
Dorota Bartusik-Aebisher

Frontiers in Oncology

doi 10.3389/fonc.2024.1373263

3,909 views
7 citations

Review

Published on 08 May 2024

Current status, challenges and prospects of antifouling materials for oncology applications

in Cancer Molecular Targets and Therapeutics

Yingfeng Zhang
Congcong Sun

Frontiers in Oncology

doi 10.3389/fonc.2024.1391293

2,103 views
2 citations

Review

Published on 02 May 2024

KRAS G12C inhibitor combination therapies: current evidence and challenge

in Cancer Molecular Targets and Therapeutics

Hirotaka Miyashita
Shumei Kato
David S. Hong

Frontiers in Oncology

doi 10.3389/fonc.2024.1380584

9,404 views
10 citations

Mini Review

Published on 02 May 2024

Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

in Cancer Molecular Targets and Therapeutics

Caroline Linde
Yu-Ting Chien
Zhiqian Chen
Qingxin Mu

Frontiers in Oncology

doi 10.3389/fonc.2024.1393492

2,148 views

Correction

Published on 01 May 2024

Corrigendum: The role of microtubules in pancreatic cancer: therapeutic progress

in Cancer Molecular Targets and Therapeutics

Mugahed Abdullah Hasan Albahde
Bulat Abdrakhimov
Guo-Qi Li
Xiaohu Zhou
Dongkai Zhou
Hao Xu
Huixiao Qian
Weilin Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1414456

645 views

Original Research

Published on 30 Apr 2024

MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon

in Cancer Molecular Targets and Therapeutics

Jitender Monga
Ritisha Ghosh
Rohith Guddeti
Dhananjay Chitale
Gazala Khan
Jagadananda Ghosh

Frontiers in Oncology

doi 10.3389/fonc.2024.1387535

1,364 views

Review

Published on 25 Apr 2024

Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression

in Cancer Molecular Targets and Therapeutics

Xia Lei
Ya Ni Gou
Jin Yong Hao
Xiao Jun Huang

Frontiers in Oncology

doi 10.3389/fonc.2024.1375729

2,793 views
1 citation

Editorial

Published on 19 Apr 2024

Editorial: Emerging anti-cancer compounds and immunomodulators for pancreatic cancer treatment

in Cancer Molecular Targets and Therapeutics

Kathleen E. DelGiorno
Stephen Safe
Jennifer M. Bailey-Lundberg

Frontiers in Oncology

doi 10.3389/fonc.2024.1411836

915 views

Clinical Trial

Published on 19 Apr 2024

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

in Cancer Molecular Targets and Therapeutics

Nebojsa Skorupan
Cody J. Peer
Xianyu Zhang
Hyoyoung Choo-Wosoba
Mehwish I. Ahmad
Min-Jung Lee
Shraddha Rastogi
Nahoko Sato
Yunkai Yu
Guillaume Joe Pegna

Frontiers in Oncology

doi 10.3389/fonc.2024.1386190

2,015 views

Review

Published on 18 Apr 2024

Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression

in Cancer Molecular Targets and Therapeutics

Hong Tian
Jia-Li Yu
Xiaoli Chu
Qi Guan
Juan Liu
Ying Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1389713

1,908 views
3 citations

Brief Research Report

Published on 18 Apr 2024

Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2

in Cancer Molecular Targets and Therapeutics

Chidiebere U. Awah
Joo Sun Mun
Aloka Paragodaarachchi
Baris Boylu
Martin Nzegwu
Hiroshi Matsui
Olorunseun Ogunwobi

Frontiers in Oncology

doi 10.3389/fonc.2024.1344852

2,029 views

Case Report

Published on 08 Apr 2024

Sunitinib for adenocarcinoma of the rete testis: a case report

in Cancer Molecular Targets and Therapeutics

Kezhen Li
Di Chen
Mingdong He
Jun Yu
Hua Mi

Frontiers in Oncology

doi 10.3389/fonc.2024.1358133

1,074 views

Navigation group

Articles

Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis

Chloroquine-induced DNA damage synergizes with DNA repair inhibitors causing cancer cell death

Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment

The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies

The use of photodynamic therapy in medical practice

Current status, challenges and prospects of antifouling materials for oncology applications

KRAS G12C inhibitor combination therapies: current evidence and challenge

Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

Corrigendum: The role of microtubules in pancreatic cancer: therapeutic progress

MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon

Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression

Editorial: Emerging anti-cancer compounds and immunomodulators for pancreatic cancer treatment

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression

Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2

Sunitinib for adenocarcinoma of the rete testis: a case report